Mayne Pharma Group Limited (MYX.AX)
AUD 6.98
(-0.29%)
AUD 6.98
(-0.29%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -174.23 Million AUD | 44.94% |
| 2023 | -316.41 Million AUD | -12.49% |
| 2022 | -281.28 Million AUD | -34.96% |
| 2021 | -208.42 Million AUD | -124.62% |
| 2020 | -92.78 Million AUD | 66.77% |
| 2019 | -279.2 Million AUD | -108.39% |
| 2018 | -133.98 Million AUD | -251.28% |
| 2017 | 88.56 Million AUD | 137.1% |
| 2016 | 37.35 Million AUD | 381.44% |
| 2015 | 7.75 Million AUD | -63.56% |
| 2014 | 21.29 Million AUD | 848.86% |
| 2013 | -2.84 Million AUD | -146.21% |
| 2012 | 6.15 Million AUD | 266.47% |
| 2011 | 1.67 Million AUD | -48.39% |
| 2010 | 3.25 Million AUD | 186.49% |
| 2009 | -3.76 Million AUD | -8.31% |
| 2008 | -3.47 Million AUD | -90.4% |
| 2007 | -1.82 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q4 | -103.68 Million AUD | 0.0% |
| 2024 Q2 | -70.55 Million AUD | 0.0% |
| 2024 FY | -174.23 Million AUD | 44.94% |
| 2023 FY | -316.41 Million AUD | -12.49% |
| 2023 Q2 | -144.57 Million AUD | 0.0% |
| 2023 Q4 | -171.84 Million AUD | 0.0% |
| 2022 Q2 | -50.37 Million AUD | 0.0% |
| 2022 FY | -281.28 Million AUD | -34.96% |
| 2022 Q4 | -212.97 Million AUD | 0.0% |
| 2021 Q2 | -181.28 Million AUD | 0.0% |
| 2021 Q4 | -27.13 Million AUD | 0.0% |
| 2021 FY | -208.42 Million AUD | -124.62% |
| 2020 FY | -92.78 Million AUD | 66.77% |
| 2020 Q2 | -17.54 Million AUD | 0.0% |
| 2020 Q4 | -75.24 Million AUD | 0.0% |
| 2019 Q4 | -283.44 Million AUD | 0.0% |
| 2019 FY | -279.2 Million AUD | -108.39% |
| 2019 Q2 | 2.58 Million AUD | 0.0% |
| 2018 Q2 | -174.2 Million AUD | 0.0% |
| 2018 FY | -133.98 Million AUD | -251.28% |
| 2018 Q4 | 40.22 Million AUD | 0.0% |
| 2017 Q2 | 72.73 Million AUD | 0.0% |
| 2017 Q4 | 15.83 Million AUD | 0.0% |
| 2017 FY | 88.56 Million AUD | 137.1% |
| 2016 FY | 37.35 Million AUD | 381.44% |
| 2016 Q4 | 18.12 Million AUD | 0.0% |
| 2016 Q2 | 19.23 Million AUD | 0.0% |
| 2015 Q4 | 3.76 Million AUD | 0.0% |
| 2015 Q2 | 3.99 Million AUD | 0.0% |
| 2015 FY | 7.75 Million AUD | -63.56% |
| 2014 Q2 | 8.42 Million AUD | 0.0% |
| 2014 FY | 21.29 Million AUD | 848.86% |
| 2014 Q4 | 12.86 Million AUD | 0.0% |
| 2013 Q4 | -297 Thousand AUD | 58.21% |
| 2013 Q3 | -710.75 Thousand AUD | 72.08% |
| 2013 Q2 | -2.54 Million AUD | 0.0% |
| 2013 FY | -2.84 Million AUD | -146.21% |
| 2012 Q2 | 1.53 Million AUD | 266.47% |
| 2012 Q3 | 1.53 Million AUD | 0.0% |
| 2012 Q4 | 1.53 Million AUD | 0.0% |
| 2012 FY | 6.15 Million AUD | 266.47% |
| 2012 Q1 | 419.75 Thousand AUD | 0.0% |
| 2011 Q4 | 419.75 Thousand AUD | 0.0% |
| 2011 FY | 1.67 Million AUD | -48.39% |
| 2011 Q3 | 419.75 Thousand AUD | 0.0% |
| 2011 Q2 | 419.75 Thousand AUD | -48.39% |
| 2011 Q1 | 813.27 Thousand AUD | 0.0% |
| 2010 Q3 | 813.27 Thousand AUD | 0.0% |
| 2010 Q4 | 813.27 Thousand AUD | 0.0% |
| 2010 Q1 | -940.32 Thousand AUD | 0.0% |
| 2010 Q2 | 813.27 Thousand AUD | 186.49% |
| 2010 FY | 3.25 Million AUD | 186.49% |
| 2009 Q3 | -940.32 Thousand AUD | 0.0% |
| 2009 Q2 | -940.32 Thousand AUD | -8.31% |
| 2009 Q1 | -868.2 Thousand AUD | 0.0% |
| 2009 Q4 | -940.32 Thousand AUD | 0.0% |
| 2009 FY | -3.76 Million AUD | -8.31% |
| 2008 Q1 | -455.99 Thousand AUD | 0.0% |
| 2008 Q4 | -868.2 Thousand AUD | 0.0% |
| 2008 Q2 | -868.2 Thousand AUD | -90.4% |
| 2008 Q3 | -868.2 Thousand AUD | 0.0% |
| 2008 FY | -3.47 Million AUD | -90.4% |
| 2007 FY | -1.82 Million AUD | 0.0% |
| 2007 Q4 | -455.99 Thousand AUD | 0.0% |
| 2007 Q3 | -455.99 Thousand AUD | 0.0% |
| 2007 Q2 | -455.99 Thousand AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Firebrick Pharma Limited | -1.17 Million AUD | -14717.445% |